Boothbay Fund Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Boothbay Fund Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,977	Closed	-$368K	–	2458
2021 Q3	$368K	Sell	20,977 -146	-0.7%	-$1.71K	0.01%	1229
2021 Q2	$205K	Buy	+21,123	New	+$199K	0.01%	1513
2019 Q4	–	Sell	-20,044	Closed	-$6K	–	1065
2019 Q3	$6K	Hold	20,044	–	–	﹤0.01%	748
2019 Q2	$7K	Hold	20,044	–	–	﹤0.01%	709
2019 Q1	$13K	Hold	20,044	–	–	﹤0.01%	729
2018 Q4	$34K	Sell	20,044 -81	-0.4%	-$243	0.01%	605
2018 Q3	$117K	Buy	+20,125	New	+$113K	0.01%	704

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Boothbay Fund Management's TRIL Position: Q4 2021 in Review

Boothbay Fund Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 20,977 shares — an estimated $368K sold.

Boothbay Fund Management first reported a position in TRIL in Q3 2018 and held it in 7 quarters. The position peaked at $368K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Boothbay Fund Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Boothbay Fund Management sold 20,977 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $368K.
Boothbay Fund Management first reported a position in Trillium Therapeutics Inc. in Q3 2018 and held it in 7 quarters.
Boothbay Fund Management's Trillium Therapeutics Inc. position peaked at $368K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.